Abstract: Provided is an isolated antigen-binding protein, which can specifically bind to CD73 and includes at least one CDR in a heavy chain variable region VH, wherein the region VH includes an amino acid sequence as represented by SEQ ID NO: 49.

Abstract: In an example, an integrated circuit structure includes a first vertical stack of horizontal nanowires laterally spaced apart from a second vertical stack of horizontal nanowires. An epitaxial source or drain structure is between the first and second vertical stacks of horizontal nanowires. The epitaxial source or drain structure includes a nucleation layer having a first portion in contact with the first vertical stack of horizontal nanowires and a second portion in contact with the second vertical stack of horizontal nanowires. The nucleation layer includes silicon with arsenic dopants. The epitaxial source or drain structure also includes an epitaxial fill layer laterally between the first and second portions of the nucleation layer. The epitaxial fill layer includes silicon with phosphorous dopants. The epitaxial fill layer has a total atomic concentration of arsenic less than half of a total atomic concentration of arsenic of the nucleation layer.

Abstract: Provided in the present application are an anti-PD-L1/TGF-? bispecific antibody and the use thereof. Specifically, provided in the present application is a bifunctional antibody, which comprises: (a) an anti-PD-L1 antibody or element; and (b) an anti-TGF-? antibody or element connected to the anti-PD-L1 antibody or element. The bifunctional antibody of the present application can simultaneously bind to TGF-? and PD-L1, thereby exerting a therapeutic effect on TGF-? and PD-L1-positive tumor cells.